Skip to main content Back to Top
Advertisement

CMS Takes on DIR Fees

Broadcast Date: March 1, 2022

 

Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

This podcast discusses the proposed rule change that CMS has made to Medicare Advantage and Part D around DIR Fees. Nick Gentile and Jillanne Schulte go through why this rule change was made, how it will effect ASHP members, and what ASHP members can do.

SPEAKERS

Jillanne Schulte WallJillanne Schulte Wall is the senior director of Health & Regulatory Policy for the American Society of Health-System Pharmacists (ASHP) in Bethesda, MD. She serves as ASHP’s primary liaison to federal regulatory agencies and, in conjunction with other members of the Government Relations team, develops and communicates of ASHP’s positions on federal and state laws, regulations, and guidance related to the profession of pharmacy.  Additionally, Jillanne works closely with stakeholders in pharmacy, medicine, manufacturing, and patient advocacy on legislative and regulatory issues of importance to ASHP members.

Nick GentileNick Gentile is the director of Political Action Committee and Grassroots Engagement for the American Society of Health-System Pharmacists. In this position, he promotes ASHP’s grassroots mobilization efforts and its political action committee, ASHP-PAC. He received his bachelor’s degree from The American University, where he majored in political science and law in society. Prior to ASHP, Nick spent ten years at the National Association of Home Builders (NAHB) working in various positions within the government affairs department. He worked with state and local government affairs issues, federal relations, grassroots mobilization and BUILD-PAC (NAHB’s political action committee).

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.